Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation

Phase 4 Completed 34 enrolled University of Sao Paulo General Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether zolendronic acid, a third generation bisphosphonate, is effective in preventing bone loss in the first year after kidney transplantation.

Timeline

Start: 2012-07
Primary completion: 2013-07
Completion: 2014-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zoledronic acid	Other / unclassified	5 mg	Intravenous

Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation

Summary

Timeline

Drugs

Indications